<?xml version="1.0" encoding="UTF-8"?>
<MedicinalProductDefinition xmlns="http://hl7.org/fhir">
	<id value="equilidem-basics"/>
	<identifier>
		<system value="http://example.org.uk/fhir/product"/>
		<value value="Equilidem25"/>
	</identifier>
	<combinedPharmaceuticalDoseForm>
		<coding>
			<system value="http://example.org.uk/fhir/dosefom"/>
			<code value="tablet"/>
		</coding>
	</combinedPharmaceuticalDoseForm>
	<indication value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age â‰¥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."/>
	<legalStatusOfSupply>
		<coding>
			<system value="http://example.org.uk/fhir/legalstatusofsupply"/>
			<code value="POM"/>
			<display value="Prescription only medicine"/>
		</coding>
	</legalStatusOfSupply>
	<classification>
		<coding>
			<system value="http://www.whocc.no/atc/example"/>
			<code value="B01A"/>
		</coding>
	</classification>
	<ingredient>
		<display value="Equilidonium Phosphate"/>
	</ingredient>
	<ingredient>
		<display value="Calcium Carbonate"/>
	</ingredient>
	<name>
		<productName value="Equilidem 2.5 mg film-coated tablets"/>
	</name>
	<crossReference>
		<product>
			<reference>
				<reference value="MedicinalProductDefinition/genericEquilidonium"/>
			</reference>
		</product>
	</crossReference>
	<manufacturingBusinessOperation>
		<manufacturer>
			<display value="EquiliDrugCo Inc."/> <!-- licence holder would use RegulatedAuthorization -->
		</manufacturer>
	</manufacturingBusinessOperation>
</MedicinalProductDefinition>